Free Trial

Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

Syndax Pharmaceuticals logo
$15.83 -0.96 (-5.72%)
(As of 11/15/2024 ET)

Syndax Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
10

Based on 11 Wall Street analysts who have issued ratings for Syndax Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a hold rating, and 10 have given a buy rating for SNDX.

Consensus Price Target

$36.00
127.42% Upside
According to the 11 analysts' twelve-month price targets for Syndax Pharmaceuticals, the average price target is $36.00. The highest price target for SNDX is $49.00, while the lowest price target for SNDX is $23.00. The average price target represents a forecasted upside of 127.42% from the current price of $15.83.
Get the Latest News and Ratings for SNDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Syndax Pharmaceuticals and its competitors.

Sign Up

SNDX Analyst Ratings Over Time

TypeCurrent Forecast
11/18/23 to 11/17/24
1 Month Ago
10/19/23 to 10/18/24
3 Months Ago
8/20/23 to 8/19/24
1 Year Ago
11/18/22 to 11/18/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$36.00$35.78$35.33$35.09
Forecasted Upside127.42% Upside81.52% Upside72.36% Upside129.80% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy

SNDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SNDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Syndax Pharmaceuticals Stock vs. The Competition

TypeSyndax PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.91
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside127.42% Upside28,591.96% Upside9.87% Upside
News Sentiment Rating
Positive News

See Recent SNDX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/12/2024HC Wainwright
2 of 5 stars
 Boost TargetBuy ➝ Buy$47.00 ➝ $49.00+191.15%
11/7/2024The Goldman Sachs Group
2 of 5 stars
 Boost TargetBuy ➝ Buy$30.00 ➝ $33.00+55.00%
10/24/2024UBS Group
4 of 5 stars
D. Dai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$37.00+99.57%
10/14/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$40.00 ➝ $41.00+115.11%
8/16/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$30.00 ➝ $34.00+70.34%
8/15/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$30.00 ➝ $31.00+53.92%
8/15/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$32.00 ➝ $33.00+63.69%
8/6/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$34.00 ➝ $33.00+65.91%
6/28/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$37.00+82.09%
6/14/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Farmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
12/22/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$45.00+123.33%
10/3/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$42.00 ➝ $43.00+218.52%
10/3/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$32.00 ➝ $28.00+107.41%
7/25/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$34.00 ➝ $36.00+65.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:25 AM ET.


SNDX Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Syndax Pharmaceuticals is $36.00, with a high forecast of $49.00 and a low forecast of $23.00.

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There is currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SNDX shares.

According to analysts, Syndax Pharmaceuticals's stock has a predicted upside of 127.42% based on their 12-month stock forecasts.

Syndax Pharmaceuticals has been rated by research analysts at HC Wainwright, Stifel Nicolaus, The Goldman Sachs Group, and UBS Group in the past 90 days.

Analysts like Syndax Pharmaceuticals more than other "medical" companies. The consensus rating score for Syndax Pharmaceuticals is 2.91 while the average consensus rating score for "medical" companies is 2.80. Learn more on how SNDX compares to other companies.


This page (NASDAQ:SNDX) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners